Australia markets closed

Landos Biopharma, Inc. (LABP)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
22.47+0.12 (+0.54%)
At close: 04:00PM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
0
0
0
18,000
0
Operating expenses
Research development
11,824
11,999
25,680
41,564
25,338
Selling general and administrative
13,719
10,728
14,881
15,252
5,338
Total operating expenses
25,543
22,727
40,561
56,816
30,676
Operating income or loss
-25,543
-22,727
-40,561
-38,816
-30,676
Interest expense
-
-
-
-
0
Total other income/expenses net
-43
-44
26
-18
77
Income before tax
-24,798
-21,935
-39,276
-38,422
-30,144
Income from continuing operations
-24,798
-21,935
-39,276
-38,422
-30,144
Net income
-24,798
-21,935
-39,276
-38,422
-30,144
Net income available to common shareholders
-24,798
-21,935
-39,276
-38,422
-30,144
Basic EPS
-3.85
-3.50
-9.76
-10.20
-7.70
Diluted EPS
-3.85
-3.50
-9.76
-10.20
-7.70
Basic average shares
5,731
6,276
4,025
3,756
3,916
Diluted average shares
5,731
6,276
4,025
3,756
3,916